Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) Document date: 2020_3_23
ID: 9hknw4ws_37
Snippet: During the follow-up period, 12 (35.3%) patients in the LPV/r group experienced adverse events including diarrhea (9/34, 26.5%), loss of appetite (5/34, 14.7%) and elevation of ALT over 2.5-fold above the normal limit (1/21, 4.8%). In addition, 5 (14.3%) patients in the arbidol group experienced adverse All rights reserved. No reuse allowed without permission......
Document: During the follow-up period, 12 (35.3%) patients in the LPV/r group experienced adverse events including diarrhea (9/34, 26.5%), loss of appetite (5/34, 14.7%) and elevation of ALT over 2.5-fold above the normal limit (1/21, 4.8%). In addition, 5 (14.3%) patients in the arbidol group experienced adverse All rights reserved. No reuse allowed without permission.
Search related documents:
Co phrase search for related documents- adverse event and arbidol group: 1, 2, 3, 4
- adverse event and follow period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- adverse event and normal limit: 1, 2, 3
- ALT elevation and follow period: 1
- ALT elevation and normal limit: 1, 2, 3, 4, 5, 6
- arbidol group and follow period: 1, 2
Co phrase search for related documents, hyperlinks ordered by date